Clinical Trial Update: A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of SGB-9768 for complement-mediated kidney diseases, including IgA nephropathy and C3 glomerulopathy, has not yet started recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Iga Nephropathy
• Immune Complex-mediated Membranoproliferative Glomerulonephritis

Drugs mentioned

• SGB-9768

Snippet

Sponsor: Suzhou Sanegene Bio Inc. | Conditions: IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Status: NOT_YET_RECRUITING